Since the mid 1900s, a significant increase of infectious, hematological and autoimmune diseases has been reported in patients with Down's syndrome (DS), independently from sex, age, family history and exposure to other risk factors, suggesting an intrinsic alterations of the immune system. Several in vitro and in vivo studies have demonstrated alterations of both cellular and humoral immunological response mainly, although not exclusively, secondary to alterations of the expression of AIRE (autoimmune regulator) gene (located on chromosome 21), leading to thymic structural and functional impairment. Autoimmune thyroid disorders (i.e.
Introduction
Down's Syndrome (DS), firstly described by J. L. Down in 1866, is the commonest chromosomal aneuploidy in live newborns and the main cause of genetic intellectual disability in Western countries [1] [2] [3] .
Estimated incidence varies from 1/700 to 1/1,500 live births, depending on prenatal diagnostic procedures, age at conception -as the risk increases with maternal age for the higher frequency of maternal chromosome 21 non-disjunction -, gestational timing of diagnosis, and case loss due to abortion. DS is caused by chromosome 21 trisomy (non-disjunction) in 95% of the cases, while the remaining ones are due to parental or de novo translocations or mosaicism [1] [2] [3] .
DS presents with pathognomonic physical characteristics, muscle hypotonia, mental retardation, accelerated and atypical ageing, and is variably associated with cardiovascular, digestive, immunological and thyroid disorders, increased risk of hematologic malignancies and early-onset Alzheimer's disease, overall strongly impacting on life quality and expectancy [2] [3] [4] .
This chapter presents the hypothetical etiopathogenic mechanisms underlying immune dysregulations in DS, describes the main features of DS-associated autoimmune endocrine diseases, and discusses unsolved issues related to their diagnostic and therapeutic management, from neonatal age to adulthood.
Mechanisms underlying immune alterations and predisposition to autoimmune diseases in patients with

Down's syndrome
Since the 1970s, various studies have been performed to identify immunological alterations responsible for the increased incidence of infections, autoimmune diseases and hematological malignancies observed in patients with DS [5] [6] [7] . Thymic atrophy and reduction in leucocytes and lymphocytes count have been repeatedly reported in these patients since the neonatal age [7] , together with an inadequate expansion of B and T lymphocytes in response to the huge exposure to environmental antigens in the first years of life, irrespective of the frequency of infections or development of autoimmunity [5; 6; 8; 9] . T lymphocytes gradually reach normal levels over the time, while B lymphocytopenia persists. Moreover, after the age of 5 years, DS subjects present with excessive IgA and IgG -with high levels of IgG1 and IgG3 and low levels of IgG2 and IgG4 -but reduced IgM, overall responsible for an exaggerated response to food antigens and auto-antigens, but a poor 4 production of natural antibodies, that worsens from childhood to adult age [7] . Moreover, a marked reduction of circulating CD4+, paralleled by an increase of CD8+ lymphocytes, has ben reported, related, at least in part, to the increase of natural killer (NK) cells expressing CD8 antigen. Finally, the percentage of CD3+ and CD5+ cells, capable of non-MHC restricted cytotoxicity, is significantly increased. These alterations could be related to both intrinsic B-cells defects and deficient T-cells help, secondary due to thymic dysfunction [5; 7] as pathognomonic histological thymic alterations, responsible for altered T-cells production and maturation, and interactions between B and T cells have been described in DS [5-7; 9] . AIRE (autoimmune regulator) gene located in the 21q22.3 region and selectively expressed in thymic medullary epithelial cells, modulates the transcription of some genes encoding for peripheral tissue-restricted antigens (TRAs), crucial for the negative selection of developing thymocytes, control of antigen presentation, chemokines' production and maturation [6; 10] . Inactivating AIRE mutations lead to autoimmune polyendocrine syndrome type I (APS1), an autosomal recessive disease that shares specific autoantibodies with DS but different disease patterns. Hypoparathyroidism and Addison's disease, hallmarks of APS1, are extremely rare in DS patients, while Hashimoto's thyroiditis, Graves' disease (GD) and type 1 diabetes mellitus are the most typical DS-associated endocrine autoimmune diseases [10] . Contrasting data regarding thymic expression of AIRE in DS have been reported. Gimenez-Barcons et al. observed a significant reduction of its expression despite the presence of three copies of the gene, suggesting overcompensation of the excess of gene dosage by post-transcriptional regulation [6] . On the contrary, Skogberg et al. reported increased AIRE levels:
given the complexity of AIRE effects on thymic function, it is not surprising that AIRE overexpression could be associated with impaired thymic function and structure [10] .
Because an adequate thymic expression of self-antigens is crucial for central tolerance, even a modest reduction may importantly contribute to the predisposition to autoimmunity, as demonstrated in patients with type 1 diabetes, myasthenia gravis and GD in which genetic polymorphisms result in reduced thymic expression of the target auto-antigens (insulin, a-chain of the acetylcholine receptor, and TSH receptor, respectively) [6; 10] . Thyroid hormones are major modulators of cell metabolism and oxidative stress, as they stimulate both catabolic and anabolic reactions, and regulate the synthesis and degradation of proteins, vitamins and antioxidant enzymes, and the mitochondrial respiratory rate [3; 15] . Data on oxidative stress associated with thyroid dysfunction are scarce and controversial. An increased oxidative stress has been reported as in both hypo-and hyperthyroidism, even in subclinical forms, despite their opposed effects on metabolism, in patients with and without DS [3] . Some alterations in the mechanisms regulating oxidative stress that may contribute to thyroid dysfunction in DS include: low levels of selenium, required for the synthesis and metabolism of thyroid hormones and functioning of selenium-dependent antioxidant enzymes, that protect the thyrocytes against peroxides; impairment of phenylalanine hydroxylase activity, converting phenylalanine in tyrosine; and DYRK1A kinase overexpression, that reduces tyrosine availability [3] .
The spectrum of thyroid disorders reported in DS include congenital hypothyroidism (1-3.6%), isolated hyperthyrotropinemia or subclinical hypothyroidism (12.5-32.9%), primary hypothyroidism (0.3-3.2%), autoimmune thyroiditis (0.3-1.4%) and hyperthyroidism (0-2%) [16] . Epidemiological, clinical and management features typical of each condition are discussed in the following paragraphs.
I. Hypothyroidism
Hypothyroidism is the most common thyroid alteration in DS. It can be congenital (incidence 1/141 live DS births vs. 1/2,500-5,000 in newborns without DS) or acquired [17] [18] [19] [20] [21] .
In the first years of life, hypothyroidism distribution is balanced between sexes, in contrast with the 6 typical association with female gender observed in non DS people. Most of the patients present with subclinical hypothyroidism (SH) or hyperthyrotropinemia, defined as mildly elevated thyroid-stimulating hormone (TSH < 10 mUI/l) in the presence of normal levels of free thyroxine (fT4) and triiodiothyronine (fT3), with no clinical symptoms or laboratory/ecographic signs of thyroid autoimmunity [22] . Thus, diagnosis is essentially made by routine biochemical screening [17-21; 23-25] .
In the majority of the cases, the underlying cause remains undetermined [17-21; 23-25] . According to a study by Luton et al. performed in 13 fetuses between 23 and 33 weeks of gestation, thyroid morphology and localization is normal, while immunohistochemistry demonstrated abnormally small and heterogeneous follicles, with delayed maturation, particularly regarding the expression of TTF1 (thyroid transcription factor 1), encoded by Nkx2.1 gene, a follicular cell marker during early development and a transcription factor involved in thyroid function later on, suggesting a primary defect in thyroid development as the basis of TSH elevation. TSH levels were >80 th percentile, and, in the great majority of the cases, fT4 levels were <50 th percentile [26] . In DS fetuses and newborns, thyroid hypoplasia is rather frequent, while thyroid agenesis, ectopy or goiter are extremely rare; anti-thyroid antibodies are detected only in a minority of patients and TSH on these data, a "wait and see" policy is recommended in DS subjects with SH, reserving treatment to overt hypothyroidism or TSH>10 μU/ml associated with goiter and/or ab-TPO, because of the increased risk of progression towards to overt HT in these cases [32] . Treatment can be also considered in SH in absence of other risk factors, but requires an off-treatment re-evaluation as the picture can resolve [3; 21; 34-36].
On the contrary, according to other authors, thyroid function screening in DS is justified because the natural history of thyroid disease is well established, the risk of silent hypothyroidism is significant, the problem is easily detectable, has a latent phase, and the treatment is easy and cheap [37] . In recent times, capillary blood sampling from a finger prick test has been proposed a less invasive, more tolerated and more practical alternative to venipuncture for thyroid screening, although it is limited to the determination of TSH, and is poorly sensitive for mildly increased TSH values (<10 mUI/l), thus requiring venipuncture in borderline cases. Mc Gowan et al. suggest annual capillary sample in children over 5 years old as it can detect elevations of TSH levels for which therapy is necessary, being the risk of decompensated hypothyroidism in patients with mildly elevated TSH very low. Venipuncture should be probably preferred as screening approach in children before 5 years of age as they are more vulnerable and even a mild thyroid insufficiency could lead to severe consequences on brain maturation [37] . 
II. Hyperthyroidism
Hyperthyroidism, although much less common than hypothyroidism, is significantly more represented in DS than in the general population (estimated prevalence 0.66-3%). It is mainly caused by Graves' disease (GD), and typically occurs between late childhood and early adulthood [24; 46; 47] .
The diagnosis is typically based on the clinical picture and not on regular screening [47] . GD in DS differs from the general population for 1) younger age at diagnosis; 2) the absence of female predominance and . On the other side, radioiodine is a definite treatment in the great majority of the cases, although the risk of secondary hypothyroidism; thus, the need of a life-long replacement therapy is high [13] . Surgery should be reserved for those with serious side effects from thyrostatic drugs or requiring rapid resolution of thyrotoxicosis, as craniofacial abnormalities and short neck could make anesthesia difficult in DS patients [24] .
Type 1 diabetes mellitus
Compared to the general population, patients with DS present a significantly higher risk to develop type 1 diabetes (DM1), being DS the most common genetic syndrome associated with DM [49] . A nationwide population-based study performed in Denmark on children born from 1981 to 2001 demonstrated a 4.2-fold increase in prevalence of DS in DM1 than in general population (0.38% vs. 0.09%), corresponding to a prevalence also more than 4-fold higher (0.7 vs. 0.17%) [50] . Previous studies reported even higher prevalence, but were biased for the study group selection and diagnostic method [50] [51] [52] . Median age of DM1 onset also appears anticipated in DS. One study performed in the 1960s showed a peak of onset at 8 years of age in DS, compared to 14 years in children without DS [53] . In another study, 22% of DS patients developed DM1 before 2 years of age, compared with only 7% of children from the general population [54] . A more recent study including 159 DS children diagnosed with DM1 demonstrated a biphasic distribution, with one peak of incidence occurring before the age of 2 years, and a second peak in the early adolescence. Moreover, DM1 in DS is often associated with other autoimmune disorders, mainly autoimmune hypothyroidism and celiac disease [49-52; 55] .
A very high frequency of anti-glutamic acid decarboxylase antibodies (GADA) has been reported in DS subjects developing DM1. Moreover, DS diabetic patients, independently from age at onset, present with DR4-DQ8/ DR3-DQ2 HLA class II genotype, which is the HLA genotype most strongly associated with DM1also in the general population, suggesting a common ethiopathogenesis. These features are similar between DS and non-DS subjects developing DM1, indicating that DM1 has the same HLA associations in DS and in the general population [51; 52; 55] .
Despite the established association between DM and DS, international guidelines for the management of subjects with DS do not provide specific indications for the optimal age and methods for screening, frequency and method for follow-up in GADA-positive patients considered at higher risk to develop DM1, nor diabetes treatment (i.e. insulin types and daily frequency of administration).
Compared to non-DS diabetic patients, DS diabetic patients tend to be treated with simpler insulin regimens -to improve the patient's and care giver's therapeutic compliance - [49; 52] , and have a better control of glycemic and blood pressure levels, possibly related to a simpler lifestyle and acceptance of routine [52; 56] .
Consequently, diabetic complications (i.e. retinopathy and nephropathy) are significantly less frequent [56] .
Final remarks and conclusions
Autoimmune disorders are significantly more common in Down's syndrome than in the general population, independently from age, sex and family history, suggesting chromosome 21 trisomy to be a risk factor per se for immune dysregulation. Autoimmune thyroiditis and type 1 diabetes mellitus are the most typical endocrine autoimmune disorders associated with DS, and often present together and in association with celiac disease. In vivo and in vitro studies have identified alterations in both B-and T-cell compartments associated with chromosome 21 trisomy, secondary to thymic dysfunction associated with impaired AIRE gene's expression. At the same, the exact etiopathogenic mechanisms underlying the predisposition of DS subjects to develop autoimmune diseases, as well as the clinical significance of mild biochemical thyroid alterations in the absence of antibodies and clinical manifestations, remain to be defined. Because the frequency of thyroid disorders and diabetes is very high and often misdiagnosed (as manifestations are unspecific and often masked by mental retardation), regular life-long screening of thyroid function and glycemic controls is strongly suggested. No general agreement exists about the optimal timing for screening, follow-up controls or for starting treatment in asymptomatic patients with mild hormonal alterations, thus management is mainly based on physician's experience and has to be individualized and tailored both on the patient's and care giver's need. Multicenter, randomized, long-term studies are strongly advised to better define the still unsolved issues and improve management of DS patients. 
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